SGD Pharma will introduce its siliconised moulded glass vials at CPHI, as the only supplier globally able to offer them to a pharmaceutical standard.
SGD Pharma’s siliconisation is an internal treatment that provides additional functionalities to a glass vial. The internal coating provides essential protection for sensitive, aggressive and viscous drug products, reducing interaction with the packaging and preserving drug product integrity.
Siliconisation is available for all glass types in vial sizes ranging from 3–500 mL in both clear and amber glass.
Siliconisation is suitable for all routes of administration (parenteral, oral, nasal). SGD Pharma’s €5 million investment in the siliconisation production line at its state-of-the-art Saint-Quentin Lamotte (SQLM) plant enables customers to receive orders of high-performance vials at speed meeting global demand.
With the increasing demand for approval of biologics, new therapeutic approaches and the development of specialty drugs, the demand for ready-to-use (RTU) packaging continues to grow.
SGD Pharma is the only supplier offering a RTU solution in moulded glass, with its Sterinity EZ-fill vials designed to meet the rigorous requirements of the pharmaceutical industry, speed up time to market and reduce total cost of ownership as a result of increased quality and flexibility.
At CPHI, SGD Pharma will present an extension to its Sterinity range. By adding a RTU Type II moulded glass vial for the first time, SGD Pharma becomes the go-to-supplier for all RTU needs.
Sterinity RTU in Type II will initially be available in size 10H with the extended range of sizes expected to be available during 2025.
Sterinity Type I is currently available in sizes 10, 20, 25, 50 and 100 mL in both clear and amber glass. Sterinity is suitable for various applications from veterinary to human health.
Olivier Rousseau, CEO, SGD Pharma, explains: “At CPHI 2024 we are showcasing solutions developed with our pharma and veterinary customers’ needs in mind, aimed at enabling them to bring their drugs to market quickly and safely."
"This commitment to innovation is reflected by our dedication to sustainability, which is an integral component of our company strategy."
"As we support the UN Global Compact for the fifth consecutive year, we are particularly proud of our progress in reducing carbon emissions at our global glass manufacturing sites."
SGD Pharma’s renewable energy initiatives, including the upgrade of our furnace at Saint Quentin Lamotte (SQLM) in France and the installation of solar panels at our Vemula, India plant, underscore an overarching focus on decarbonisation with the company-wide goal to cut emissions recorded in 2020, by 35% by 2030 and by 65% by 2040."
"These efforts reflect our responsibility to our customers, partners and the planet as we strive for a safer and healthier environment.”